Abstract
Aim
Our aim was to confirm that preoperative CA 125 serum level can be useful for discrimination between benign and malignant masses in the pelvis.
Methods
Preoperative CA 125 serum level was analyzed retrospectively in 121 patients who had surgery because of a malignant ovarian tumor and in 91 patients with benign masses in the pelvis. The cutoff serum level CA 125 between benign and malignant masses in the pelvis was 35 and 65 IU/ml.
Results
Of those patients with a malignant ovarian tumor, 65.3% had menopause whereas only 31.5% of those with a benign tumor did so. The average age of the patients with a malignant tumor was 54.2 years and of those with a benign tumor 46.8 years. The preoperative CA 125 serum level was higher than 35 IU/ml in 80.2% and higher than 65 IU/ml in 72.7% of all analyzed patients with a malignant tumor, whereas it was 23.9% and 9.8% respectively in patients with a benign mass. In early stage ovarian cancer disease (borderline stage, I/II) the preoperative CA 125 serum level was higher than 35 IU/ml in 67.8% and in 52.5% higher than 65 IU/ml. In advanced stages (III/IV), it was higher than 35 and 65 IU/ml in 96.1%. After therapy the CA 125 serum level dropped below 35 IU/ml in 70.8% and after three chemotherapy courses in 78.1%. A CA 125 level less than 35 IU/ml was achieved by therapy in 84.2% patients with an early stage disease (I/II) and in 62.1% in advanced stages (III/IV). The calculated sensitivity was 80.2% and negative 74.5% (CA 125 higher than 35 IU/ml) and 72.7%, 90.2%, 90.7%, 71.6% respectively (CA 125 higher than 65 IU/ml).
Conclusion
Preoperative determination of CA 125 is a very useful method to discriminate between benign and malignant masses in the pelvis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RC, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337
Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (1983) A radioimmunoassay icing a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887
But I, Gorisek B (1996) Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer. Gynecol Oncol 63:166–172
Cruickshank DJ, Fullerton WT (1987) The clinical significance of preoperative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 94:692–695
De Brujin HW, van der Zee AG, Aalders JG (1997) The value of cancer antigen125 (CA 125) during treatment and follow-up of patients with ovarian cancer. (Review, 64 refs). Curr Opin Obstet Gynecol 9:8–13
Ferrero JM, Largillier R, Ramaioli A, Heudier P, Teissier E, Namer M (1997) Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors. Bull Cancer 84:722–728
Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE (1996) Relationship of preoperative serum CA 125 to survival in epithelial ovarian carcinoma. J Reprod Med 41:140–142
Gonzales A, Vizoso F, Vazquez J, Ruibal A, Balibrea JL (1997) Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian carcinoma. Int J Biol 12:112–117
Harlozinska A, Sedlaczek P, Van Valen A, Rozdolski K, Einarsson R (1997) TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms. Anticancer Res 17:4473–4478
Hata K, Hata T, Manbe A, Sugimura K, Kitao M (1992) A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol 80:922–926
Hawkins RE, Roberts K, Wiltshaw E, Munday J, McCready VR (1989) The clinical correlates of serum CA 125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer 60:634–637
Jacobs I, Oram D, Faibanks J, Turner J, Frost C, Grudzinskas JG (1990) A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 922–929
Jacobs IJ, Oram DH, Bast RC Jr (1992) Strategies for improving the specificity of screening for ovarian cancer with tumor associated antigens CA 125, CA 15–3, and TAG 72, 3. Obstet Gynecol 80:396–399
Kurjak A, Pasalic L, Marton U, Kupesic S Ilijas M, Pavlic Z (1994) Screening or early detection of ovarian cancer. Gynaecol Perinatol 3:75–81
Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC (1987) CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69:223–227
Malkasian GD, Knapp RC, Lavin PT (1988) Preoperative evaluation of serum CA 125 levels in premenopausal patient with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynaecol 159:341–346
Masahashi T, Matsuzawa KK, Ohsawa M, Narita O, Asai T, Ishiharan M (1988) Serum CA 125 antigen levels in patients with endometriosis: changes in CA 125 levels during menstruation. Obstet Gynecol 72:328–331
Meier W, Stieber P, Hasholzner U, Fateh-Moghadam A (1997) Prognostic significance of CA 125 in patients with ovarian cancer and secondary debulking surgery. Anticancer Res 17:2945–2947
Mimica M (1993) Preoperative serum CA 125 levels in patients with ovarian tumors. Gynaecol Perinatol 2:71–74
Onsrud M, Shabana A, Austgulen R (1996) Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumour Biol 17:90–96
Paavonen J, Miettinen A, Heinonen PK, Aaran RK, Rejsala K, Aine R, Punnonen R, Laine S, Kaillioniemi OP, Lehtinen M (1989) Serum CA 125 in acute pelvic inflammatory disease. Br J Obstet Gynaecol 96:574–579
Wiener Z, Thaler I, Beck D, Rottem S, Deutch M, Brandes JM (1992) Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 159–162
Woolas JW, Jacobs I, Xu F, Oram DH, Bast RC (1993) Serum levels of CA 125, M-CSF and OVX 1 in stage 1 and preclinical ovarian cancer. Abst Br Gynaecol Cancer Soc 2
Zaneta G, Valle C, Trio D, Ragoni G, Pitelli MR, Pallerino A (1993) Usefulness of color Doppler ultrasound in discriminating benign from ovarian malignant masses before surgery. Ultrasound Obstet Gynecol 3 [Suppl 1]:21
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Milojkovic, M., Hrgovic, Z., Hrgovic, I. et al. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet 269, 176–180 (2004). https://doi.org/10.1007/s00404-002-0411-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-002-0411-7